We are live on ! Find out more
OMC

OUP Management Company Portfolio holdings

AUM $44.5M
1-Year Est. Return 55.11%
This Fund
S&P 500
This Quarter Est. Return
-22.47%
1 Year Est. Return
+55.11%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$131M
AUM Growth
-$90.5M
Cap. Flow
-$20.9M
Cap. Flow %
-15.91%
Top 10 Hldgs %
93.12%
Holding
16
New
–
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$5.43M

Top Sells

Rank Stock Value
1
IONQ icon
IonQ
IONQ
+$24.6M
2
SERA icon
Sera Prognostics
SERA
+$1.76M

Sector Composition

Rank Sector Weight
1 Healthcare 73.79%
2 Technology 22.53%
3 Industrials 3.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONQ icon
1
IonQ
IONQ
$15.1B
$29.6M 22.53%
2,319,519
-1,827,562
-44% -$24.6M
CNTA
2
DELISTED
Centessa Pharmaceuticals
CNTA
$26.4M 20.06%
2,937,615
+595,724
+25% +$5.43M
PMVP icon
3
PMV Pharmaceuticals
PMVP
$61.3M
$20.6M 15.68%
989,232
– –
JBIO
4
Jade Biosciences
JBIO
$1.34B
$11.1M 8.43%
17,250
– –
DICE
5
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$10.3M 7.82%
536,693
– –
CYT
6
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$9.33M 7.1%
2,474,572
– –
EVLV icon
7
Evolv Technologies
EVLV
$1.07B
$4.83M 3.67%
1,820,866
– –
EFTR
8
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$4.11M 3.13%
41,028
– –
DTIL icon
9
Precision BioSciences
DTIL
$188M
$3.46M 2.64%
37,464
– –
LABP
10
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$2.7M 2.05%
182,748
– –
VOR icon
11
Vor Biopharma
VOR
$1.25B
$2.26M 1.72%
18,736
– –
SPRO icon
12
Spero Therapeutics
SPRO
$72.4M
$2.17M 1.65%
249,070
– –
LENZ
13
LENZ Therapeutics
LENZ
$162M
$2.07M 1.58%
58,044
– –
SERA icon
14
Sera Prognostics
SERA
$77.5M
$1.28M 0.97%
337,505
-303,856
-47% -$1.76M
RNAC icon
15
Cartesian Therapeutics
RNAC
$253M
$1.06M 0.81%
28,751
– –
QTTB icon
16
Q32 Bio
QTTB
$482M
$195K 0.15%
3,556
– –

Similar funds

JMF
Johnson Midwest Financial Glidden, Iowa $44.7M AUM 21.66% 1-Year Est. Return
AMC
Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return
MCAV
Meritech Capital Associates VI Palo Alto, California $45.3M AUM 4.6% 1-Year Est. Return
SIP
Scott Investment Partners Henley-On-Thames, United Kingdom $43.5M AUM 17.97% 1-Year Est. Return
KXA
KPCB XIV Associates Menlo Park, California $42.8M AUM 16.52% 1-Year Est. Return
WRCAI
West Rim Capital Associates II Lehi, Utah $46.8M AUM 11.72% 1-Year Est. Return
MAM
Must Asset Management Seoul, South Korea $40.9M AUM 22.53% 1-Year Est. Return
GIA
G2VP I Associates Portola Valley, California $48.2M AUM 37.59% 1-Year Est. Return

OUP Management Company's Q1 2022 Portfolio in Review

As of Q1 2022, OUP Management Company held 16 positions worth $131M, down 41% from $222M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

OUP Management Company withdrew a net $20.9M in Q1 2022, reducing 2 holdings. Its largest reduction was IonQ, cutting an estimated $24.6M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 65% a quarter earlier, followed by Technology and Industrials.

Against the trend, OUP Management Company added an estimated $5.43M to Centessa Pharmaceuticals.

  • OUP Management Company added most to Centessa Pharmaceuticals in Q1 2022, an estimated $5.43M increase.
  • OUP Management Company's biggest Q1 2022 reduction was IonQ, cutting an estimated $24.6M.
  • OUP Management Company's ten largest holdings make up 93% of its $131M portfolio in Q1 2022.
  • OUP Management Company opened 0 new positions and closed 0 in Q1 2022.
  • OUP Management Company's portfolio value fell 41% quarter-over-quarter to $131M.

Based on OUP Management Company's 13F filing for Q1 2022, filed 4 May 2022.